Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Novartis CEO Says U.S. Exit From Global Health Programmes to Affect Millions

Published by Global Banking & Finance Review®

Posted on January 31, 2025

1 min read

Last updated: January 26, 2026

Add as preferred source on Google

Novartis CEO Vas Narasimhan discusses U.S. exit from global health programs - Global Banking & Finance Review — The image features Novartis CEO Vas Narasimhan addressing concerns about the U.S. withdrawal from global health programs, emphasizing its impact on millions relying on critical health initiatives.

Tags:Public Health financial management corporate governance

Quick Summary

Novartis CEO warns that US withdrawal from WHO could impact millions relying on health programs. Key initiatives like HIV/AIDS and malaria are at risk.

Novartis CEO Warns U.S. Withdrawal from Health Programs Could Impact Millions

FRANKFURT (Reuters) - The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization and related programmes risks harming millions of people worldwide.

"I don't think there's a lot of logic in stopping these programmes, (some of which were) actually started by Republican administrations, ... given the millions of people who rely on these programmes to get the medicines that they need," CEO Vas Narasimhan said at a news conference after the release of quarterly financial results.

There is a lot of pressure on initiatives that have lost funding, including a U.S. push to fight HIV/AIDS and malaria abroad, he said.

The CEO added the company and its own global commitments, such as work on neglected tropical diseases, were not affected.

(Reporting by Ludwig Burger, editing by Thomas Seythal)

Key Takeaways

•Novartis CEO warns of US exit from WHO.
•Millions may be affected by halted health programs.
•Programs at risk include HIV/AIDS and malaria initiatives.
•US withdrawal lacks logic, says CEO Vas Narasimhan.
•Novartis' commitments to global health remain unaffected.

Frequently Asked Questions about Novartis CEO says U.S. exit from global health programmes to affect millions

1What did the Novartis CEO say about the U.S. exit from health programs?

The CEO warned that the U.S. exit from the World Health Organization and related programs risks harming millions of people who rely on these initiatives.

2What specific health initiatives are at risk due to U.S. funding cuts?

There is significant pressure on initiatives that have lost funding, particularly those aimed at fighting HIV/AIDS and malaria abroad.

3How is Novartis affected by the U.S. withdrawal from global health programs?

The CEO stated that Novartis' own global commitments, such as work on neglected tropical diseases, are not affected by the U.S. withdrawal.

Novartis CEO Warns U.S. Withdrawal from Health Programs Could Impact Millions

There is a lot of pressure on initiatives that have lost funding, including a U.S. push to fight HIV/AIDS and malaria abroad, he said.

The CEO added the company and its own global commitments, such as work on neglected tropical diseases, were not affected.

(Reporting by Ludwig Burger, editing by Thomas Seythal)

Frequently Asked Questions

1What did the Novartis CEO say about the U.S. exit from health programs?

The CEO warned that the U.S. exit from the World Health Organization and related programs risks harming millions of people who rely on these initiatives.

2What specific health initiatives are at risk due to U.S. funding cuts?

There is significant pressure on initiatives that have lost funding, particularly those aimed at fighting HIV/AIDS and malaria abroad.

3How is Novartis affected by the U.S. withdrawal from global health programs?

The CEO stated that Novartis' own global commitments, such as work on neglected tropical diseases, are not affected by the U.S. withdrawal.